ANTİNEOPLASTİK MARUZİYETİNİN
SAĞLIK ÇALIŞANLARININ ÜREME
SAĞLIĞI ÜZERİNE ETKİLERİ
Hastanelerde bulunan çeşitli kimyasal ve ilaçlara maruz kalmanın personel sağlığı üzerindeki etkileri yaygın biçimde araştırılmaktadır. Gelişmiş ülkelerde, bu konuda yapılmış çok sayıdaki epidemiyolojik araştırmaların ışığında güvenli çalışma protokolleri geliştirilmiştir. Bu önlemler antineoplastiklerin yaygın olarak kullanıldığı onkoloji kliniği, klinik farmakoloji üniteleri ve ilgili sağlık personelini de kapsamaktadır. Araştırmalar maruziyet bulgularının önlemlere rağmen devam ettiğine işaret etmektedir. Antineoplastik ilaçların elde taşınması, hazırlanması ve hatta kemoterapi alan hastaların klinik bakımı, sorumlu personelin üreme sağlığı üzerinde olumsuz etkiler yaratabilir. Dolayısıyla ilgili birimlerde çalışan ve özellikle aktif üreme çağında olan kadın sağlık personelinin konu ile ilgili endişeleri süregelmektedir. Bu endişeler arasında düşükler ve konjenital anomaliler ilk sıraları alsa da intrauterin gelişme geriliği, ölü doğum, preterm doğum gibi etkiler de bazı çalışmalarca ileri sürülmüştür. Bu nedenle hastanelerde antineoplastik ilaçlarla çalışan kadın sağlık personelinin üreme sağlığı üzerindeki olası etkilerini literatürdeki verileri gözden geçirerek netleştirmeye çalışacağız.
EFFECTS OF OCCUPATIONAL
ANTINEOPLASTIC EXPOSURE
ON REPRODUCTIVE HEALTH OF
HEALTHCARE PERSONNEL
Occupational hazards have been studied in detail for their impact on healthcare workers in hospitals. In the light of many epidemiologic studies on the issue, standard safety protocols have been issued in developed countries. These protocols cover for places where routine antineoplastic medications are used, such as clinical pharmacology units, oncology clinics and for related healthcare personnel. Despite these precautions, studies continued to point exposure findings. Handling and preparation of antineoplastic medications or even caring of chemotherapy patients may cause adverse outcomes on reproductive health of personnel. Such a possibility is continued to generate significant concern among personnel who is working with antineoplastic medications, especially among female workers in their reproductive age. Even though these concerns are mainly for miscarriages and congenital anomalies, some studies have also suggested possible risks for stillbirth, intrauterine growth retardation, preterm delivery and infertility. Therefore we will attempt to clarify
___
- 1. Ricci MS, Zong WX. Chemotherapeutic approaches
for targeting cell death pathways. Oncologist
2006;11(4):342-57.
- 2. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M,
Rahman MF, Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis
2007;22(6):395-401.
- 3. Cavallo D, Ursini CL, Perniconi B, Francesco AD, Giglio
M, Rubino FM, Marinaccio A, Iavicoli S. Evaluation of
genotoxic effects induced by exposure to antineoplastic
drugs in lymphocytes and exfoliated buccal cells of
oncology nurses and pharmacy employees Mutat Res.
2005;587(1-2):45-51.
- 4. Sessink PJ, Van de Kerkhof MC, Anzion RB, Noordhoek
J, Bos RP. Environmental contamination and assessment
of exposure to antineoplastic agents by determination of
cyclophosphamide in urine of exposed pharmacy technicians:
is skin absorption an important exposure route?
Arch Environ Health 1994;49(3):165-9.
- 5. Connor TH, DeBord DG, Pretty JR, Oliver MS, Roth TS,
Lees PS, Krieg EF Jr, Rogers B, Escalante CP, Toennis CA,
Clark JC, Johnson BC, McDiarmid MA. Evaluation of antineoplastic
drug exposure of health care workers at three
university-based US cancer centers. J Occup Environ
Med 2010;52(10):1019-27.
- 6. National Institute for Occupational Safety and Health
(NIOSH). NIOSH alert: preventing occupational exposures
to antineoplastic and other hazardous drugs in health
care settings. http://www.cdc.gov/niosh/docs/2004-165/
pdfs/2004-165.pdf. DHHS (NIOSH) publication no.
2004–165:2004.
- 7. Fransman W, Roeleveld N, Peelen S, de Kort W, Kromhout
H, Heederik D. Nurses with dermal exposure to antineoplastic
drugs: reproductive outcomes. Epidemiology
2007;18(1):112-9.
- 8. Fransman W, Vermeulen R, Kromhout H. Dermal exposure
to cyclophosphamide in hospitals during preparation,
nursing and cleaning activities. Int Arch Occup Environ
Health 2005;78(5):403-12.
- 9. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars
RF, Anzion R, Vermeulen R.Ann. Postulating a
dermal pathway for exposure to anti-neoplastic drugs
among hospital workers. Applying a conceptual model
to the results of three workplace surveys. Occup Hyg
2000;44(7):551-60.
- 10. Baykal U, Seren S, Sokmen S. A description of oncology
nurses’ working conditions in Turkey. Eur J Oncol Nurs
2009;13(5):368-75.
- 11. Fransman W, Vermeulen R, Kromhout H. Occupational
dermal exposure to cyclophosphamide in Dutch hospitals:
a pilot study. Ann Occup Hyg 2004;48(3):237-44.
- 12. Kiffmeyer TK, Kube C, Opiolka S, Schmidt KG, Schöppe
G, Sessink. Va¬por pressures, evaporation behaviour
and airborne concentrations of hazardous drugs: implications
for occupational safety. PJM Pharmeaceut J 2002
268:331–337.
- 13. Connor TH, Shults M, Fraser MP. Determination of the
vaporization of solutions of mutagenic antineoplastic
agents at 23 and 37 degrees C using a desiccator technique.
Mutat Res 2000 ;470(1):85-92.
- 14. US Department of Labor. OSHA, Office of Occupational
Medicine. Guidelines for cytotoxic (antineoplastic) drugs.
http://www.osha.gov.
15. Oncology Nursing Society. Standards for Cancer Nursing
Practice. 1982.
- 16. American Society of Hospital Pharmacists. Technical assistance
bulletin on handling cytotoxic drugs in hospitals.
Am J Hosp Pharm 1985;42:131-137.
- 17. https://osha.europa.eu/en. European Agency for Safety
and Health at Work (EU-OSHA) web site.
18. http://www.esop.li. European Society of Oncology Pharmacology
web site.
- 19. http://eur-lex.europa.eu/en/index.htm. European Comission
Legislation web site.
- 20. Quansah R, Jaakkola JJ. Occupational exposures and adverse
pregnancy outcomes among nurses: a systematic
review and meta-analysis. J Womens Health (Larchmt)
2010;19(10):1851-62.
- 21. R.J.M. Gardner, Grant R. Sutherland. Gametogenesis and
Conception, Pregnancy Loss and Infertility. In: Chromosome
Abnormalities and Genetic Counseling. 3rd edition,
New York: Oxford University Press; 2004.p.341-360.
- 22. Lawson CC, Rocheleau CM, Whelan EA, Lividoti Hibert
EN, Grajewski B, Spiegelman D, Rich-Edwards JW. Occupational
exposures among nurses and risk of spontaneous
abortion. Am J Obstet Gynecol 2012;206(4):327.e1-8.
- 23. http://www.nhs3.org Nurses’ Health Study Official Web
Page.
- 24. Stücker I, Caillard JF, Collin R, Gout M, Poyen D, Hémon
D. Scand. Risk of spontaneous abortion among nurses
handling antineoplastic drugs. J Work Environ Health
1990;16(2):102-7.
- 25. Valanis B, Vollmer WM, Steele P. Occupational exposure
to antineoplastic agents: self-reported miscarriages and
stillbirths among nurses and pharmacists. J Occup Environ
Med 1999;41(8):632-8.
- 26. Selevan SG, Lindbohm ML, Hornung RW, Hemminki K.
A study of occupational exposure to antineoplastic drugs
and fetal loss in nurses. N Engl J Med 1985;313(19):1173-
8.
- 27. Dranitsaris G, Johnston M, Poirier S, Schueller T, Milliken
D, Green E, Zanke. Are health care providers who work
with cancer drugs at an increased risk for toxic events? A
systematic review and meta-analysis of the literature. B.J
Oncol Pharm Pract 2005;11(2):69-78.
- 28. McDonald AD, McDonald JC, Armstrong B, Cherry NM,
Côté R, Lavoie J, Nolin AD, Robert D. Fetal death and
work in pregnancy. Br J Ind Med 1988;45(3):148-57.
- 29. Ratner PA, Spinelli JJ, Beking K, Lorenzi M, Chow Y,
Teschke K, Le ND, Gallagher RP, Dimich-Ward H. Cancer
incidence and adverse pregnancy outcome in registered
nurses potentially exposed to antineoplastic drugs. BMC
Nurs 2010;9:15.